Publications

ssessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.

Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk . and Cholesterol Treatment Trialists' (CTT) Collaboration ., (2026), Lancet

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D. et al, (2025), Am J Kidney Dis

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis.

Herrington WG. et al, (2025), Lancet Diabetes Endocrinol, 13, 1003 - 1014

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.

Mach F. et al, (2025), Eur Heart J, 46, 4359 - 4378

Estimating the long-term effects of aspirin for primary prevention.

Baigent C. et al, (2025), Eur Heart J, 46, 4423 - 4425

[2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias].

Mach F. et al, (2025), G Ital Cardiol (Rome), 26, e1 - e20

Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition.

Malijan GB. et al, (2025), Kidney Int Rep, 10, 4090 - 4093

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Malijan GB. et al, (2025), Am J Kidney Dis

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.

Mach F. et al, (2025), Atherosclerosis, 409

Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.

Baigent C. and Sádaba R., (2025), Eur Heart J, 46, 3151 - 3153

Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.

Hammami I. et al, (2025), Heart, 111, 716 - 721

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.

Zhou J. et al, (2025), EClinicalMedicine, 85

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Judge PK. et al, (2025), Nephrol Dial Transplant, 40, 1175 - 1186

2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations II: diagnostic tests and prediction models.

Di Angelantonio E. et al, (2025), Eur Heart J, 46, 1895 - 1906

2024 Revision of the level of evidence grading system for ESC clinical practice guideline recommendations I: therapy and prevention.

Jüni P. et al, (2025), Eur Heart J, 46, 1885 - 1894

Cookies on this website

Search results (347)